Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Bio Bridge Science (CE) Charts. Click Here for more Bio Bridge Science (CE) Charts.](/p.php?pid=staticchart&s=NO%5EBGES&p=8&t=15)
Bio-Bridge Science, Inc. (OTCBB: BGES) today announced
that it has entered into an exclusive distribution agreement with
Xinhua Surgical Instruments Co., Ltd., located in Shandong, China.
Under the agreement, Bio-Bridge Science has been granted exclusive
distribution rights for all Xinhua surgical instruments in the United
States, which are subject to FDA approval.
Dr. Liang Qiao, Chairman and CEO of Bio-Bridge Science said, "We
believe that our agreement with Xinhua will enable us to create a
revenue stream as we develop our vaccine program. We are pleased to be
able to offer Xinhua surgical instruments to potential U.S. customers.
Xinhua surgical instruments are manufactured with German technology
and expertise, giving them competitive advantages in product surface,
corrosion resistance, performance, as well as price. We believe our
knowledge of the Chinese and American medical market should allow us
to be effective in introducing the products in the United States."
About the Company
Bio-Bridge Science, Inc. is a biotechnology firm focused on the
development of vaccines with broad therapeutic and preventive
applications. Through its wholly owned subsidiary in Beijing,
Bio-Bridge is developing a HIV Vaccine, that is expected to enter
clinical trials early next year in China. The vaccine, based on
exclusive technology co-developed by CEO Liang Qiao, an associate
professor at Loyola University Chicago's Stritch School of Medicine,
is designed to target infection in mucosal tissues, the first type of
tissue attacked by HIV.
About Xinhua
Xinhua Surgical Instruments Co. Ltd. is a world leader in surgical
instrument production that is based in Shandong, China
Forward Looking Statements
This press release contains forward-looking statements as defined
by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to
uncertainties and risks including, but not limited to, product and
service demand and acceptance, changes in technology, economic
conditions, the impact of competition and pricing, government
regulation, and other risks defined in this document and in statements
filed from time to time with the Securities and Exchange Commission.
All such forward-looking statements, whether written or oral, and
whether made by or on behalf of the company, are expressly qualified
by these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition, the
company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date hereof.
Please refer to SEC filings for additional information and
accompanying notes to financial statements.